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One major barrier the HCMV vaccine field has faced is the lack of a highly-translatable 72 animal model of congenital virus transmission. For the past 50 years, vaccine efficacy studies 73 that evaluate protection against congenital HCMV transmission have been reliant upon either 74
(1) small-animal models using species-specific viruses with limited HCMV sequence homology 75 or (2) costly and arduous human clinical trials. We recently reported on the first nonhuman 76 primate (NHP) model of congenital CMV transmission following primary infection of rhesus 77 monkey dams with rhesus CMV (RhCMV), 24 which is genetically more similar to HCMV than 78 guinea pig or murine CMV. [24] [25] [26] Our study established that RhCMV could cross the placenta and 79 cause congenital infection following intravenous (IV) inoculation of either immune competent or 80 CD4+ T cell-depleted seronegative dams during the second trimester of pregnancy. The IV 81 route of RhCMV inoculation was selected for this experimental congenital infection model over 82 mucosal routes of exposure as it induced reproducible high levels of viremia and virus shedding 83 in the urine and saliva of infected macaques, and hence best mirrored the prerequisite for 84 systemic CMV replication prior to placental virus transmission in congenital CMV infection. In 85 this study, we observed that CD4+ T cell-depleted dams frequently aborted their fetus following 86 virus inoculation, exhibited higher plasma and amniotic fluid viral loads, and had delayed 87 production of autologous neutralizing antibodies. 88
These results suggested that maternal humoral immunity may impact systemic and 89 intrauterine RhCMV replication, thereby influencing the severity of congenital infection. As such, 90 we sought to use this NHP model to investigate whether preexisting antibody alone, in the 91 absence of virus-specific T cell responses, could protect against placental RhCMV transmission 92 or reduce congenital RhCMV infection severity. The passive infusion of antibodies in this study 93
was not intended to model a treatment strategy for the prevention of either maternal CMV 94 acquisition or fetal virus transmission, but rather as means to understand the protection 95 conferred by preexisting maternal antibody. These insights will inform rational development of a 96 5 vaccine to elicit the most critical immune responses required to eliminate congenital HCMV 97 disease. 98 140 of antibody responses to primary viral infections, we attributed early detection of RhCMV-141 specific activity (within the first 10 days) to reflect passively-infused antibodies in the HIG 142 preparations. Peak RhCMV-binding IgG as well as RhgB and RhPC-specific antibody titers in 143 the high-potency HIG group surpassed those of the standard HIG group (Fig. 3B-D) , while peak 144 neutralization titers were similar between the two HIG groups (Fig. 3E-F ). However, levels of 145 IgG binding and antibody neutralization were sustained near peak levels for 10 days in the 146 dose-optimized, high-potency HIG group compared to only 3 days in the standard HIG group 147 ( Fig. 3B-E) . It is noteworthy that average binding IgG and epithelial cell neutralization titers in 148 the high-potency HIG group surpassed those of chronically-infected rhesus monkeys ( Fig. 3B ,E, 149 Fig. S5 ). 24 The standard HIG group had the most robust natural host immune response, with a 150 8 sustained elevation of RhCMV-specific IgM (Fig. 3A) , as well as an exponential rise in binding 151 IgG ( Fig. 3B ) and neutralization titers ( Fig. 3D ,E) that outpaced each of the other groups. 152
153 RhCMV viral load, placental transmission, and shedding. Following RhCMV inoculation, both 154 control and standard HIG group animals showed a rapid onset of viremia that peaked at 2 155 weeks post infection (Fig. 4A) . In contrast, peak viremia in the high-potency HIG group was 156 delayed until 4 weeks post infection (Fig. 4A) , with a median value nearly two logs lower than 157 the control group ( Fig. 4E; p=0 .047, corrected Wilcoxon exact test). RhCMV DNA copies in 158 amniotic fluid were used as a marker for placental virus transmission because it is the gold-159 standard clinical test for congenital HCMV infection. 29 All 6 control animals had detectable 160
RhCMV DNA in amniotic fluid between 1 and 3 weeks following infection ( remained uninfected whereas all 3 fetuses in the high-potency HIG group were protected from 193 infection ( Fig. 6C ), suggesting that preexisting, potently CMV-neutralizing HIG can reduce the 194 incidence of congenital infection. Of note, fetal growth curves ( Table S3 ). 204 205 Placental transcriptome. Congenital RhCMV infection appears to modify the placental 206 transcriptome more radically than HIG infusion or fetal abortion, as more than 300 genes were 207 differentially-expressed between RhCMV-transmitting and nontransmitting dams, but only 78 208 when comparing HIG infusion/fetal outcome ( Fig. 7A, Fig. S10 ). This finding suggests that HIG 209 predominantly mediated protection through its impact on maternal systemic virus replication 210 rather than through modification of the placental transcriptome. A large proportion of these 211 differentially-expressed genes were immune-related. Additional cellular functions that appeared 212 altered by RhCMV infection included metabolism, oxidoreductase activity, and cellular 213 growth/proliferation (Table S4 ). Gene interaction analysis of differentially-expressed genes 214 between RhCMV-transmitting and nontransmitting dams ( Fig. 7B ) revealed that the placental 215 transcriptome was heavily biased towards up-regulation of genes in transmission. Furthermore, 216 certain gene nodes had numerous connections to other differentially regulated genes (e.g. 217 VCAM1, EGFR, GZMB, LYN, FYN, GAPDH), suggesting that these "keystone" genes are 218 central to the cellular pathways induced by RhCMV infection. Focusing on a subset of genes 219 involved in innate vs. adaptive immunity ( Fig. 7C ), we note that there is a potential bias for 220 activation of innate immune pathways by placental RhCMV infection. Finally, cell type 221 enrichment analysis based upon previously-described genes involved in cellular 222 activation/processes 31 demonstrated no preference at the transcriptome level for myeloid vs. 223 lymphoid lineages ( Fig. 7D ). However, Natural Killer (NK) cell-specific genes had the most 224 robust differential expression ( Fig. 7D ), and we identified 21 unique genes known to be 225 associated with NK cell function and/or chemotaxis ( Fig. 7E , Table S5 ) including killer 226 immunoglobulin-like receptors (KIR2DL4) and killer lectin-like receptors (KLRD1, KLRC1, 227 KLRC3, KLRB1). Furthermore, non-classical MHC molecules HLA-E and HLA-G (rhesus analog 228 inferred by IPA database) were up-regulated. 229
Discussion: 230
The role of preexisting antibodies in prevention of congenital HCMV infection remains 231 controversial within the HCMV vaccine field, yet our findings indicate that a dose-optimized 232 preinfusion with potently-neutralizing HIG can block placental RhCMV transmission in a rhesus 233 monkey model of congenital CMV. Our study illustrates that factors such as maternal antibody 234 titer and neutralization potency at the time of peak CMV viremia may be important 235 considerations for antibody-mediated protection against congenital CMV infection. In this study, 236
given the experimental setup, we have not definitively proven that it is neutralization titer (and 237 not other factors such as total amount of binding antibody, antibody-dependent cellular 238 cytotoxicity, or reduction in maternal viral load) that is protective against congenital RhCMV 239 transmission. Nevertheless, these data substantiate observational human cohort studies 240
suggesting that maternal HCMV-specific antibodies decrease risk of placental virus 241 transmission. 20-22,32 Furthermore, these data affirm findings from the guinea pig model of 242 congenital infection that demonstrate that preexisting antibodies (from either glycoprotein 243 immunization or passive HIG/monoclonal antibody infusion) can reduce the incidence and/or 244 severity of congenital gpCMV infection. 33-36 245
The therapeutic efficacy of HIG in preventing placental transmission in mothers with 246 primary HCMV infection is a topic of ongoing investigation. Several non-randomized small-scale 247 clinical trials 37,38 and a case-control study 39 concluded that post-infection HIG infusion 248 significantly reduced rates of placental HCMV transmission and improved infant outcomes. 249
Animal studies in the guinea pig model of congenital infection further corroborated these 250 findings. 35,40 However, it was perhaps unsurprising when a large-scale, randomized, placebo-251 controlled trial did not find significant reduction in rates of congenital infection in mothers with 252 primary HCMV infection that were subsequently treated with HIG, and revealed no difference in 253 virus-specific antibody titers, effector T cell count, or the level of plasma viremia between the 254 HIG-treated and placebo groups. 23 Several confounding factors may explain the lack of efficacy 255 13 of HIG treatment in this large-scale clinical trial. First, it was unknown in this study whether 256 congenital transmission had already occurred prior to initiating therapeutic HIG treatment. 257
Second, there is no concrete evidence for the therapeutic efficacy of the clinically-utilized 258 product (Cytotect ® ), and therefore it is unknown whether HIG infusion achieved a titer that was 259 both sustained and/or sufficient for effective anti-HCMV immunity. 260
This study was not intended to model a therapeutic treatment regimen but rather to 261 directly address the clinical question: can preexisting antibodies alone prevent congenital CMV 262 infection? The advantages of our NHP model are that the timing of infection is predefined and 263 serum antibody titer can be titrated. By utilizing passive infusion experiments with different 264 dosing regimens and potency of RhCMV-specific antibodies prior to RhCMV inoculation, we 265 were able to model the requirements for preexisting antibodies to confer protection against 266 congenital RhCMV infection. Moreover, conducting the experiments in a CD4+ T cell-depletion 267 model also allowed us to address the protective role of antibodies to the exclusion of RhCMV-268 specific cellular immune responses. Our results suggest that a single 100mg/kg dose of 269 standard neutralizing potency HIG (donor plasma screened by elevated ELISA OD, as is done 270 for the clinical product Cytotect ® 41 ) delivered immediately prior to RhCMV infection can reduce 271 the severity of congenital infection (0 of 3 monkeys aborted) but is insufficient to prevent 272 congenital CMV transmission (2 of 3 monkeys transmitted). However, a dose-optimized 273 preinfusion of a higher neutralizing potency HIG product may be more effective in preventing 274 and/or decreasing the severity of congenital infection. 275
To our knowledge, the epitope specificity of RhCMV-neutralizing antibodies has not 276 been previously reported. It has been well established for HCMV that, while gB is an important 277 target of neutralizing antibodies, the majority of neutralization activity in seropositive individuals 278 is directed against the gH/gL/UL128-131A pentameric complex. 42,43 Furthermore, the 279 pentameric complex has also been shown to be a target of neutralizing antibodies for guinea pig 280
CMV. 44 In this study, we identified that antibodies targeting both RhgB and RhPC contribute to 281 14 the total neutralization activity of RhCMV-seropositive monkey sera in approximately equivalent 282 proportions ( Fig. 2 ). It is certainly reassuring for the translational applicability of this animal 283 model system that RhPC-directed antibodies are neutralizing; however, it is unclear why the 284 relative proportions of PC-directed neutralization activity would differ between HCMV (~85%) 42 285 and RhCMV (~50%). We hypothesize that this could explain why the magnitude of RhCMV 286 neutralizing antibody titers are roughly equivalent magnitude when measured in both fibroblasts 287 and epithelial cells ( Fig. 3) , whereas HCMV neutralizing antibody titers are nearly an order of 288 magnitude lower in fibroblasts than epithelial cells. 45 Subsequent studies are needed to improve 289 our understanding of this potential difference in viral biology and/or antiviral humoral immune 290
factors between RhCMV and HCMV. 291
It has been theorized that passively-infused antibodies can reduce systemic maternal 292 viral load and thereby reduce the likelihood of placental transmission, 20,37 though this correlation 293 has not been observed in some human primary infection cohorts. 46 In this study, dams with 294 reduced peak plasma viral load in the presence of antibodies did not transmit the infection to 295 their fetus in utero (Fig. 4E ). This trend was accompanied by a significant reduction in 296 nucleotide diversity of the plasma virus population in the high-potency HIG group, assessed at 297 both the gB and gL loci ( Fig. 5, Fig. S7 ). Thus, we hypothesize that in the setting of antibody-298 mediated immune pressure, the number of unique viral variants is restricted following primary 299 infection and systemic replication is inhibited, resulting in decreased viral transmission to the 300 fetus. 301
The placental transcriptome was examined to investigate whether HIG-mediated 302 protection against congenital infection occurs via gene regulation at the level of the 303 placenta/decidua. Intriguingly, RhCMV infection impacted the transcription profile of 304 placental/decidual cells to a much greater degree than HIG-treatment or fetal abortion, 305
suggesting that HIG predominantly mediated protection through its impact on maternal systemic 306 virus replication. The preferential activation of innate over adaptive immune processes in 307
RhCMV-infected placenta (Fig. 7D) is perhaps due to the tolerogenic environment at the 308 maternofetal interface. 47,48 Furthermore, the apparent upregulation of NK cell-specific genes in 309
RhCMV-infected placenta (Fig. 7D ,E) may be attributable to either NK cells being the major 310 leukocyte in the decidua during the early stages of pregnancy 49 or by the propensity for NK cells 311
to control CMV infection in vivo. 50,51 312
Our findings are based on a relatively small cohort of animals (n=12) due to the severely 313 limited availability of breeding, seronegative female monkeys. One consequence of our limited 314 animal population is the need to amplify the biologic effects of placental RhCMV infection 315 through both CD4+ T cell depletion and IV viral inoculation. Though both these artificial methods 316 distort the reality of natural CMV infection and bias our results in favor of placental transmission, 317
we propose that these interventions strengthen the major finding in this study that preexisting 318 antibody alone (in the absence of cell-mediated immunity) can prevent placental transmission in 319 the setting of acute maternal viremia. One additional limitation to our study design is that, 320 though HIG is known to non-specifically modulate immune responses to prevent inflammatory 321 disease, 52-54 we had to limit the number of individual control groups in this study and did not 322 have a cohort of animals infused with non RhCMV-reactive HIG. Because of this deficiency, we 323 cannot definitively rule out non-specific immunomodulatory effects of the infused HIG, though all 324 infusion groups had similar cytokine expression profiles following infection ( Fig. S9) . 325
Furthermore, since protection against congenital transmission may have been achieved as a 326 result of a "dose-effect" in the high-potency HIG group vs. the standard group, antibody-327 mediated protection is likely due to anti-viral function rather than immunomodulatory properties 328 of the infused HIG. 329
Despite these limitations, this is the first primate study to demonstrate that preexisting 330 maternal antibody alone has the potential to block and ameliorate placental CMV transmission. 331
Thus, a maternal vaccine that elicits durable, potently-neutralizing humoral immunity could be 332 an ideal intervention to eliminate pediatric disabilities associated with congenital HCMV 333 16 infection. Based on our findings we hypothesize that the prevention of maternal HCMV 334 acquisition (i.e. sterilizing immunity), which has been the target of several phase II vaccine 335 trials, 13,14 may not be the most appropriate measurable outcome for a congenital HCMV vaccine 336 that ultimately seeks a reduction in the frequency of congenital HCMV transmission. Since we 337 observed that antibody-mediated protection against congenital HCMV was associated with a 338 decrease in maternal systemic viral load and constrained viral diversity, these surrogate 339 markers could potentially serve as clinical study endpoints. Subsequent studies should 340 investigate the epitope specificity and properties of protective immunoglobulins for future 341 rational design of a maternal congenital HCMV vaccine. 342
Methods: 343
Animals. Indian-origin rhesus macaques were housed at the Tulane Primate National Research 344
Center and maintained in accordance with institutional and federal guidelines for the care and 345 use of laboratory animals. 55 All females were from the expanded specific pathogen-free (eSPF) 346 colony and confirmed to be RhCMV seronegative by whole-viron ELISA screening for RhCMV-347 specific IgM and IgG plasma antibodies. RhCMV-seronegative males and females were then 348 co-housed and females were screened every 3 weeks for pregnancy via abdominal ultrasound. 349
All animals in this study were between 4 and 9 years of age at the time of pregnancy/enrollment 350 modeling of the neutralization activity from the standard group (Fig. S4 ). 6 dams were non-367 infused control animals (including 4 historical controls) 24 . 368
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Blood draws were performed on the standard potency infused animals on the following 369 days after infection/infusion: 0, 2, 4, 7, 10, 14, 21, 28, 35, 42. The high-potency infused animals 370 were sampled at days: 0, 1, 2, 3, 4, 7, 10, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, 84. Amniotic 371 fluid (by amniocentesis), urine (by clean pan collection), and saliva (by oral saline wash), were 372 also collected on all animals on a weekly to biweekly intervals until fetal harvest. In the case of 373 fetal abortion, placental and fetal products were obtained from the cage and fixed in formalin for 374 hematoxylin-eosin staining and immunohistochemistry or frozen. Fetal growth was monitored 375 by measuring biparietal diameter and femur length during weekly to biweekly fetal sonography 376 over the course of gestation. Sonography was also used to screen for signs of congenital 377
RhCMV-associated sequelae. The fetuses of dams in the standard HIG group were harvested 378 at 6 weeks following infection, and those of the high-potency HIG group at 12 weeks following 379 infection. Amicon 30K filters (Fisher Scientific). Final preparations were tested by ELISA for the presence 393 of bacterial endotoxin. See quality control sheet for high-potency HIG preparation in Fig. S3 . 394
IgG in rhesus monkeys were adjusted using baseline value of IgG for each individual animal 397 and analyzed using WinNonlin (version 6.3.0; Certara). One-and two-compartment PK models 398 with first-order elimination were evaluated to characterize the observed data. PK parameters 399 including clearance (CL), volume of distribution (V), and half-life associated with the elimination 400 phase (T 1/2,β ) were estimated for each animal. Simulations for optimizing dosing regimen in the 401 second PK study were performed to ensure IgG concentrations above 1-1.2 mg/ml (~ID 50 >1000) 402 for 2 weeks after initiating treatment. Epithelial-tropic UCD52 and UCD59 were propagated on MKE cells for 3-4 passages, 412 then passaged once on TeloRF cells in order to increase viral titer. This single round of 413 fibroblast amplification was intended to minimize any alteration of viral tropism or glycoprotein 414 surface expression. Virus infections were performed with similar media but with 5% FCS for 4h 415 at 37°C and 5% CO 2 . Virus was harvested when cells showed 90% cytopathic effects (CPE) by 416 cell scraping. For harvest, infected cells were pelleted by low-speed centrifugation, and the 417 supernatant was placed on ice. Cell pellets were then resuspended in infection media and 418 subjected to three rounds of freeze/thaw cycles. Following centrifugation, supernatants were 419 combined, passed through a 0.45μm filter, overlaid onto a 20% sucrose cushion, and 420 20 ultracentrifuged at 70,000×g for 2h at 4 °C using an SW28 Beckman Coulter rotor. Virus pellets 421 were resuspended in DMEM containing 10% FCS and titered in TeloRFs using the 422 TCID 50 method of Reed and Muench. 423 424
Characterization of T cells by flow cytometry. Maternal peripheral CD4+ and CD8+ T cells were 425
phenotyped by mixing 100µL of EDTA-anticoagulated blood with a pool of fluorescently labeled 426 monoclonal antibodies including CCR7, CD95, CD28, CD4, CD20, CD3, CD8, and CD45 ( Table  427 S1). After a 30 min incubation at 4°C, cells were washed with PBS supplemented with 2% FCS 428 and pelleted at 100×g for 5 min. Red blood cells were then lysed by adding 1×BD lysis buffer for 429 40min at room temperature. Intact cells were centrifuged at 150×g for 5 min, washed once with 430 PBS containing 2% FCS, and resuspended in 100µL of PBS with 2% FCS. Cells were fixed by 431 adding 15µL of 2% formaldehyde and processed by flow cytometry. Gating of CD4+ and CD8+ 432 populations/subpopulations was completed in FlowJo as is outlined in Fig. S1 . were deparaffinized in xylene, rehydrated in graded alcohol, and subsequently blocked with 487 0.3% hydrogen peroxide in PBS for 30min. Pretreatment involved microwaving for 20min in 488 0.01% citrate buffer (Vector laboratories), followed by 45min of cooling at room temperature. 489
Following pretreatment, an avidin-biotin block (Invitrogen) and protein block with 10% normal 490 goat serum (NGS) were conducted on all sections. A wash of Tris-buffered saline with 0.5% 491
Tween-20 followed each step. Sections were incubated with anti-RhCMV IE1 polyclonal rabbit 492 sera (kindly provided by P.A.B.) at a 1:1,600 dilution for 30 min at room temperature. Slides 493 were then incubated with biotinylated goat anti-rabbit IgG (Invitrogen) at a 1:200 dilution in NGS 494 for 30min at room temperature. This was followed by 30min incubation at room temperature with 495 R.T.U. Vectastain ABC (Vector Laboratories). Immunolabeling was visualized using 496 diaminobenzidine and counterstained with Mayer's hematoxylin. Irrelevant, isotype-matched 497 primary antibodies were used in place of the test antibody as negative controls in all 498 immunohistochemical studies. Positive control tissues consisted of archived rhesus macaque 499 lung and testis from an RhCMV-seropositive animal. 500 501 Viral DNA isolation and assessment of viral load. RhCMV viral load was measured in plasma, 502 AF, saliva, urine, and tissues by quantitative RhCMV-specific PCR following DNA extraction. 503
Urine and mouth washes were concentrated using Ultracel YM-100 filters (Amicon) and frozen 504 for subsequent DNA extraction. DNA was extracted from urine using the QIAmp RNA minikit 505 (Qiagen), from AF/saliva/plasma by using the QIAmp DNA minikit, and from snap-frozen tissue 506 (10-25mg) after overnight Proteinase K digestion using the DNeasy Blood and Tissue kit 507 (Qiagen). RhCMV DNA was quantitated by real-time PCR using the 5′-508 GTTTAGGGAACCGCCATTCTG-3′ forward primer, 5′-GTATCCGCGTTCCAATGCA-3′ reverse 509 primer, and 5′-FAM-TCCAGCCTCCATAGCCGGGAAGG-TAMRA-3′ probe, which amplify and 510 detect a 108-bp region of the RhCMV IE1 gene. 56 Between 5-10ng of DNA was added as 511 template to 50µL of 1×PCR mixture containing 300nM of each primer, 100nM probe, 2mM 512 MgCl 2 , 200µM each of dATP, dCTP, and dGTP, 400µM dUTP, 0.01U/µL Amperase UNG, 513 0.025U/µL Taq polymerase, and reaction buffer that includes passive reference dye ROX. PCR 514 conditions consisted of an initial 2min cycle at 50°C followed by 10min at 95°C and 45 cycles of 515 denaturation at 95°C for 15s and combined annealing/extension at 60°C for 1min. Data are 516 expressed as copies per milliliter for plasma/AF and as copies per microgram input DNA for 517 tissues/saliva/urine. RhCMV DNA was quantitated using a standard consisting of a plasmid 518 containing the entire RhCMV IE1 gene. RhCMV DNA was detected with a linear dynamic range 519 from 10 0 to 10 6 copies in the presence of genomic DNA. each primer set we confirmed that there was no significant primer bias through mixing viral DNA 542 in known ratios and applying the SNAPP technique (Fig. S6) . 543 544 SNAPP amplicon reconstruction and nucleotide diversity. Sequences of the targeted regions on 545 the genes gB and gL were reconstructed by merging the paired reads sets using the PEAR 546 software under default parameters. 57 The fused reads were then filtered using the extractor tool 547 25 from the SeekDeep pipeline (http:// baileylab.umassmed.edu/seekdeep), filtering sequences 548 according to their length, overall quality scores and presence of the primer sequences. To 549 homogenize the number of sequences per sample due to variable coverage, a random set of at 550 most 10,000 sequences was retrieved from each sample to estimate strain frequency and 551 nucleotide diversity. The number of sequences analyzed per sample varied from 2,000-10,000, 552 depending on the sample coverage. Next, haplotype reconstruction was performed using the 553 qluster tool from SeekDeep, which accounts for possible sequencing errors by collapsing 554 fragments with mismatches at low quality positions. For each given sample, the haplotypes had 555 to be present in two sample replicates to be taken into account. Each haplotype was assigned 556 to 1 of the 3 inoculated viral strains by first calculating the nucleotide distance (nucleotide 557 substitutions) between the haplotype and the reference viral strain, then assigning the haplotype 558 to the strain with the shortest nucleotide distance. Nucleotide diversity was computed as the 559 average distance between each possible pair of sequences belonging to the same reference 560 strain. 58 561
562
Placental RNA isolation and microarray. Tissue sections weighing approximately 30mg were 563 obtained from flash frozen, full-thickness rhesus placenta/decidua, lysed using a TissueLyser LT 564 (Qiagen), then total RNA extracted using an RNeasy Mini Kit (Qiagen). RNA was assessed for 565 quality with Agilent 2100 Bioanalyzer G2939A (Agilent Technologies) and Nanodrop 8000 566 spectrophotometer (Thermo Scientific/Nanodrop) and confirmed to have: A 260 /A 280 >1.8, 567
A 260 /A 230 >1.0, and RIN>7.0. Hybridization targets were prepared with MessageAmp™ Premier 568 RNA Amplification Kit (Applied Biosystems/Ambion) from total RNA, hybridized to Affymetrix 569 GeneChip ® Rhesus Macaque Genome arrays in Affymetrix GeneChip ® hybridization oven 645, 570 washed in Affymetrix GeneChip ® Fluidics Station 450 and scanned with Affymetrix GeneChip ® 571
Scanner 7G according to standard Affymetrix GeneChip ® Hybridization, Wash, and Stain 572 protocols (Affymetrix). Affymetrix microarray data was initially processed, underwent QC, and 573 26 was normalized with the robust multi-array average method using the affy 59 Bioconductor 60 574 package from the R statistical programming environment (R studio version 0.99.902). 575
Differential expression was carried out using a moderated t-statistic from the limma 61 package. 576
The false discovery rate was used to control for multiple hypothesis testing. Gene set 577 enrichment analysis 62 was performed to identify differentially regulated pathways and gene 578 ontology terms for each of the comparisons performed. Gene sets specific for innate/adaptive 579 immunity, myeloid/lymphoid lineages, and immune cell specific were obtained from previous 580 reports 31 and supplemented from the literature such that each comparison group had >25 581 characteristic genes (gene lists available upon request). Gene networks were constructed using 582 NatureAnalyst 63 , with first order gene interactions inferred from the InnateDB interactome ( Fig.  583 7B) 64 . Genes related to NK cell function (Table S5) For sequence diversity analysis (Fig. 5, Fig. S7 
